Tuebingen, 4. April 2013 - immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announces today that the Company’s Chief Scientific Officer, Dr Harpreet Singh, is to present at the 2013 American Association for Cancer Research (AACR) Annual Meeting in Washington D.C. on Tuesday, 9 April at 11.30am EDT (5.30pm CET).
Dr Singh will talk about the use of preclinically well characterized naturally presented tumor antigens combined with systematic clinical immunomonitoring and cellular/serum biomarker screening as guiding tools in the rational development of novel cancer vaccines. Details of the talk are as follow:
Session: Major Symposium
Presentation number: SY27-03
Presentation Title: Biomarker-guided development of novel multi-peptide cancer vaccines - from discovery to phase lll trials Session Chair: Glenn Dranoff
Location: Room 202, Washington Convention Center
In addition, immatics will present a poster on: “Impact of various first- and second-generation tyrosine-kinase inhibitors on frequency and functionality of immune cells”. Details are as follow:
Session: Immune Therapies: Adoptive Cellular Therapies and Combinations
Poster board number: 12
Abstract number: 3971
Presentation time: Tuesday, 9 April, 1-5pm EDT (7-11pm CET)
Location: Hall A-C, Poster section 22
For additional information on immatics please visit www.immatics.com or contact:
Paul Higham, CEO
Dr. Nikola Wiegeler, Assistant to the Management
immatics biotechnologies GmbH
Phone: +49 7071 5397 110
E-mail: media@immatics.com
Citigate Dewe Rogerson
David Dible / Chris Gardner / Sita Shah
Phone: +44 207 638 9571
E-mail: david.dible@citigatedr.co.uk
About immatics
immatics biotechnologies is a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer. immatics’ lead product, IMA901, is in a pivotal phase 3 study after completing a successful randomized phase 2 trial in renal cell carcinoma. immatics’ pipeline also includes IMA910, which has reported improved overall survival data in patients with advanced colorectal cancer (phase 1/2 study completed), and IMA950, which is in phase 1 in patients with glioma.
immatics’ unique technology platform XPRESIDENTTM discovers novel relevant cancer antigens known to be expressed on tumor cells, tumor-associated peptides (TUMAPs), as the basis for its vaccines. In contrast to widely used existing in silico and indirect methods to identify peptide antigens immatics’ TUMAPs are confirmed to be naturally expressed in primary cancer tissue. TUMAPs activate white blood cells (so called cytotoxic T cells) against tumor cells. immatics’ vaccines contain multiple TUMAPs to maximize the chances of clinical success by increasing the number of targets on cancer cells that they address. Phase 2 results with IMA901 and IMA910 have shown significantly better survival in patients who respond to multiple TUMAPs in both of these vaccines.
immatics’ multi-peptide vaccines are ‘drug like’, i.e. fully synthetic, off-the-shelf, easily scalable and stable.
immatics is based in Tuebingen and Martinsried (Munich), Germany.
